Information Provided By: 
Fly News Breaks for May 22, 2019
KIN
May 22, 2019 | 16:27 EDT
Stifel analyst Jonathan Block initiated Kindred Biosciences with a Buy rating and a $14 price target. The analyst believes "the real value creation to Kindred's story will be its robust pipeline of monoclonal antibodies," including its "MAB candidates such as epoCat for feline anemia, a multi-pronged approach toward atopic dermatitis and other offerings for indications like inflammatory bowel disease in dogs."
News For KIN From the Last 2 Days
There are no results for your query KIN
